R1507 + bevacizumab + erlotinib

R1507 + bevacizumab + erlotinib is a **combination therapy** of three distinct agents, investigated together for synergistic antitumor efficacy. - **R1507** is a fully human IgG1 monoclonal antibody that inhibits the insulin-like growth factor 1 receptor (IGF-1R), thereby blocking IGF-1R-mediated signaling involved in tumor growth and survival. Developed by Genmab in collaboration with Roche, its development was discontinued after early-phase trials where it showed activity especially in sarcoma and other solid tumors[1][2][4][5]. - **Bevacizumab** is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thus inhibiting angiogenesis in tumors. - **Erlotinib** is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, blocking pathways involved in cell proliferation and survival. The combination regimen was explored in the context of advanced solid tumors, especially in scenarios where multiple pathways—tumor growth signals (IGF1R), angiogenesis (VEGFA), and cell proliferation (EGFR)—were implicated, but is not an approved therapy and was primarily studied in early-phase trials.

Other names

R1507 + bevacizumab + erlotinib